How to bill a referral: New patient or consultation?

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 8
Volume 17
Issue 8

A common conundrum that community oncologists face in their practices is whether to bill a first encounter with a new patient referred by another physician as a consultation or as a new patient visit. Making the distinction may seem like splitting hairs, but the Centers for Medicare and Medicaid Services (CMS) has very specific billing criteria on this issue.

ABSTRACT: Mixing and matching the Medicare codes for a new patient and a consultation may seem like no big deal, but Medicare has definite ideas about these two encounters. Avoid a billing headache by erring on the side of caution.

A common conundrum that community oncologists face in their practices is whether to bill a first encounter with a new patient referred by another physician as a consultation or as a new patient visit. Making the distinction may seem like splitting hairs, but the Centers for Medicare and Medicaid Services (CMS) has very specific billing criteria on this issue.

CMS requires the following criteria for reimbursing a consultation:

  • “A physician’s opinion or advice regarding the evaluation and management (E&M) of a specific medical issue is requested by another physician;

  • The request for the consultation must be documented by the consultant in the patient’s record; and

  • A written report containing the findings is provided to the referring physician” (Practical Tips for the Oncology Practice, 4th edition, ASCO, 2007, p. 50).

A new patient encounter requires a transfer of care from the referring physician to the consulting physician, according to Medicare. CMS suggests that an encounter should be billed as a new patient visit unless the referring physician plans to treat the patient based on advice from the consultant.

As for consultations, according to CMS, billing an encounter as a consultation is proper when the specialist directly treats the patient but the referring physician retains responsibility for the patient’s general care.

Needless to say, complaints have been lodged that CMS guidance on what constitutes a transfer of care is confusing and ambiguous. In an effort to clear up the confusion, CMS has been asked to clarify its guidelines by a consortium of societies, including ASCO and the Society of Gynecologic Oncologists.

In an October 2006 letter to the CMS, the societies take issue with the CMS’ use of the term “complete care for the condition,” when a patient shifts from one physician to another. “It is unclear whether this means that physicians performing consultations are precluded from billing for an initial consultation if any transfer of care is involved,” the letter stated. As of July 2008, CMS had not responded to the requests in the letter.

To be on the safe side, a first meeting with a new referred patient should be coded as a new patient visit. If the oncologist assumes responsibility for care of the referred patient after the initial consultation, the subsequent codes used should be visit codes, not consultation codes. Finally, initial encounters with patients who self-refer for a second opinion can be billed as new patient visits.

CCP&P welcomes questions from our readers on practice management. Please forward question or comments to Ronald.Piana@cmpmedica.com.

Recent Videos
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Related Content